Showing results (2431-2440 of 2,573) with videos related to
Sort By:
Pageof 258
Molecular Metabolism|December 10, 2021
Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetesChieh-Hsin Yang, Danise Ann-Onda, Xuzhu Lin, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 7, 2025
MTCH2 Suppresses Thermogenesis by Regulating Autophagy in Adipose TissueXin-Yuan Zhao, Ben-Chi Zhao, Hui-Lin Li, et al.Science (New York, N.Y.)|July 22, 2010
Association of trypanolytic ApoL1 variants with kidney disease in African AmericansGiulio Genovese, David J Friedman, Michael D Ross, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancerUdai Banerji, D Ross Camidge, Henk M W Verheul, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 26, 2015
ABH-Glycan Microarray Characterizes ABO Subtype Antibodies: Fine Specificity of Immune Tolerance After ABO-Incompatible TransplantationM Jeyakanthan, P J Meloncelli, L Zou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2019
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung CancerAlice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2019
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortNeal E Ready, Patrick A Ott, Matthew D Hellmann, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2018
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic EventsTerry L Ng, Derek E Smith, Rao Mushtaq, et al.Pediatric Nephrology (Berlin, Germany)|June 26, 2023
Urinary TIMP-2*IGFBP-7 to diagnose acute kidney injury in children receiving cisplatinHayton Chui, Kelly R McMahon, Shahrad Rod Rassekh, et al.Pageof 258